Advertisement

Uroonkologie pp 123-167 | Cite as

Grundlagen der systemischen Therapie

  • Martin Schuler
  • Tobias Jäger
  • S. Krege
  • Herbert Rübben
  • Christian Doehn
  • Dieter Jocham
Chapter
  • 1k Downloads

Zusammenfassung

Die Einführung sog. »zielgerichteter Medikamente« hat einen Paradigmenwechsel in der Systemtherapic maligner Erkrankungen ausgelöst. Voraussetzung hierfür waren die in den letzten 25 Jahren gesammelten Erkenntnisse der molekularbiologischen, molekulargenetischen und immunologischen Grundlagenforschung, die ein besseres Verständnis der pathogenetischen Prozesse im Rahmen der malignen Transformation und Tumorprogression sowie die Identifikation strategischer Zielstrukturen (»Targets«) ermöglichen. Auf diese Weise wurde ein neuer Ansatz der Entwicklung antineoplastischer Therapeutika angestoßen, der auf die Wirkung an spezifischen Molekülaktivitäten und nicht primär auf zelluläre Endpunkte (Wachstumshemmung, Zelltod) ausgerichtet ist.

Literatur

Literatur 10.1

  1. Astrinidis A, Henske EP (2005) Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 24(50): 7475–81PubMedGoogle Scholar
  2. Hilger RA, Scheulen ME, Strumberg, D (2002) The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 25: 511–518PubMedGoogle Scholar
  3. Meiler J, Schuler M (2006) Therapeutic targeting of apoptotic pathways in cancer. Curr Drug Targets 7: 1361–1369PubMedGoogle Scholar
  4. Weis SM, Cheresh DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437: 497–504PubMedGoogle Scholar
  5. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong, H (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099–7109PubMedGoogle Scholar

Literatur zu Kap. 10.2

  1. Aapro M (2005) Optimising antiemetic therapy: what are the problems and how can they be overcome? Curr Med Res Opin 21 (6): 885–897PubMedGoogle Scholar
  2. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (5): 909–918PubMedGoogle Scholar
  3. Barth J, Kloke M (2003) Paravasation bei Zytostatika. In: Seeber S, Schütte J (Hrsg) Therapiekonzepte Onkologie, 4. Aufl. Springer, Berlin Heidelberg New York Tokio, 2003, S 1708–1715Google Scholar
  4. Basser RL, Green MD (1994) Pulmonary toxicities. In: Kirkwood JM, Lotze MT, Yasko JM (eds). Current cancer therapeutics. Current Medicine, Philadelphia, pp 272–278Google Scholar
  5. Bellone JD (1981) Treatment of vincristin extravasation. JAMA 245: 343PubMedGoogle Scholar
  6. Billingham ME, Mason GW, Bristow MR et al. (1978) Anthracycline cardiomyopathy monitored by morphological changes. Cancer Treat Pep 62: 865–872Google Scholar
  7. Bokemeyer C, Oechsle K, Hartmann JT, Schoffski P, Schleucher N, Metzner B, Schleicher J, Kanz L. (2002) Treatment-induced anaemia and ist potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer 87 (10): 1066–1071PubMedGoogle Scholar
  8. Bokemeyer C, Schmoll HJ, Polivoda H (1994) Sekundäre Leukämien nach Etoposid-haltiger Chamotherapie. Dtsch Med Wochenschr 119: 707–713PubMedGoogle Scholar
  9. Bowyer GW, Davies TW (1987) Methotrexate toxicity associated with an ileal conduit. Br J Urol 60: 592PubMedGoogle Scholar
  10. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Hassison D (1978) Early anthracycline cardiotoxicity. Am J Med 65: 823–832PubMedGoogle Scholar
  11. Bronchud MH, Scarffe JH, Thatcher N (1988) Phase I/II study of recombinant human granulocyte colonystimulating factor in patients receiving intensive chemotherapy for small cell lung cancer recombinant human granulocyte-macrophage colonystimulating factor in AIDS (letter). N Eng J Med 318: 579Google Scholar
  12. Bronner A, Hood A (1983) Cutaneous complications of chemotherapeutic agents. J Am Acad Dermatol 9: 646–666Google Scholar
  13. Canon JL (2005) Final Results of a Randomized, Double-Blind, Active-Controlled Trial of Darbepoetin alfa Administered Once Every 3 Weeks (Q3 W) for the Treatment of Anemia in Patients Receiving Multicycle Chemotherapy. Proc ASCO 23: 8284Google Scholar
  14. Carmichael DJS (1992) Handling of drugs in kidney disease. In: Cameron S, Davison AM, Grünfeld JP, Kerr D, Ritz E (eds) Oxford text-book of clinical nephrology. Univ Press Oxford, pp 175–196Google Scholar
  15. Cooper JAD Jr, White DA, Matthay RA (1986) Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis 133: 321–340PubMedGoogle Scholar
  16. De Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ (2003) Addition of the oral NK1 antagonist aprpitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatinbased chemotherapy. J Clin Oncol 21(22): 4105–11PubMedGoogle Scholar
  17. Di Lorenzo G, Autorino R, DArmiento FP, Mignogna C, De Laurentiis M, De Sio M, Darmiento M, Damiano R, Vecchio G, De Placido S (2004) Expression of proto-oncogene c-kit in high risk prostate cancer. Eur J Surg Oncol 30(9): 987–92PubMedGoogle Scholar
  18. Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, DArmiento M, Bianco AR, De Placido S (2004) HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori 90(2): 163–70PubMedGoogle Scholar
  19. Drasga RE, Einhorn LH, Williams SD, Patel DN, Stevens EE (1983) Fertility after chemotherapy for testicular cancer. J Clin Oncol 1: 179–183PubMedGoogle Scholar
  20. Du XX, Williams DA (1994) Interleukin 11: a multifunctional growth factor derived from the hematopoitic microenvironment. Blood 83: 2023–2030PubMedGoogle Scholar
  21. Fink U, Peters HD, Schmoll HJ (1987) Antiemetische Therapie. In: Schmoll H-J, Peter H-D, Fink U (Hrsg) Kompendium internistische Onkologie. Springer, Berlin Heidelberg New York Tokyo, S 317–345Google Scholar
  22. Fossa SD, Ous S, Abyholm T, Norman N, Loeb M (1985) Post-treatment fertility in patients with testicular cancer. II. Influence of cis-platinbased combination chemotherapy and of retroperitoneal surgery on hormone and sperm cell production. Br J Urol 57: 210–214PubMedGoogle Scholar
  23. Fossa SD, Heilo A, Botinger O (1990) Unexpected high serum levels in cystectomiced bladder cancer patients with an ileas conduit treated intermediate doses of the drug. J Urol 143: 498PubMedGoogle Scholar
  24. Gabrilove JL, Jakukowski A, Scher H (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell-carcinoma of the urothelium. N Engl J Med 318: 1414PubMedGoogle Scholar
  25. Gallmeier WM (1979) Zytostatikum para: was tun? Münch Med Wochenschr 121: 11Google Scholar
  26. Golde DW (1990) Hämatopoetine gleichen Abwehrschwäche aus. Oncol Rev 5/2: 6Google Scholar
  27. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group (2003) The oral neurokin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22): 4112–4119PubMedGoogle Scholar
  28. Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39(8): 1074–80PubMedGoogle Scholar
  29. Hofer MD, Fecko A, Shen R, Setlur SR, Pienta KG, Tomlins SA, Chinnaiyan AM, Rubin MA (2004) Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 6(5): 503–12PubMedGoogle Scholar
  30. Ignoffo RJ, Friedman A (1980) Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17PubMedGoogle Scholar
  31. Kaplan RS, Wiernik PH (1982) Neurotoxicity of antineoplastic drugs. Semin Oncol 9: 103–130PubMedGoogle Scholar
  32. Köstering H, Nagel G (1982) Prophylaxe und Therapie von Zystostatika-Hautnekrosen. Onkologie: 3: 317Google Scholar
  33. Krege S (2003) Chemotherapy of advanced urological tumors. Onkologie Suppl 4: 13–7Google Scholar
  34. Kreisman H, Wolkove N (1992) Pulmonary toxicity of antineiplastic therapy. In: Perry MC (ed) The chemotherapy source book. Williams & Wilkins, Baltimore, pp 598–619Google Scholar
  35. Kuderer et al. (2005) Meta-analysis of prophylactic granulocyte-colony-stimulating-factor (G-CSF) in cancer patients receiving chemotherapy. Proc ASCO 2005; 23: # 8117 AbstractGoogle Scholar
  36. La Bianca R, Beratta G, Cleric M et al. (1982) Cardiac toxicity of 5-fluorouracil: a study of 1083 patients. Tumori 68: 505–510Google Scholar
  37. Lara PN Jr, Twardowski P, Quinn DI (2004) Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer 3 (3): 165–173PubMedGoogle Scholar
  38. Larson DL (1982) Treatment of tissue extravasation by antitumor agents. Cancer 49: 1796PubMedGoogle Scholar
  39. Leyden M, Sullivan J (1983) Full-Sickness skin-necrosis due to inadvertent interstitiell infusion of cis-platin. Cancer Treal Rep 67: 199Google Scholar
  40. Miller RS, Freiha FS, Torti FM (1991) Surgical restaging of PTS with advanced TCC of the urothelium treated with CHV. Proc ASCO 10: 530Google Scholar
  41. National Cancer Institute (NCI) (1993) Investigator’s handbook. A manual for participants in clinical trials of investigational agents. Cancer therapy evaluation program. Diversion of cancer treatment. National Cancer Institute, Bethesda/MDGoogle Scholar
  42. Nichols CR, Breeden ES, Loehrer PJ, Williams SD, Einhorn LH (1993) Secondary leukemia associated with a conventional dose of etoposide. J Natl Cancer Inst 85: 36–40PubMedGoogle Scholar
  43. Perez CA, Brady LW (1993) Principles and practice of radiation oncology, 2nd edn. Lippincott, Philadelphia, pp 51–55Google Scholar
  44. Petersen PM, Hansen SW, Giwercman A, Rorth M, Stakkebaek NE (1994) Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol 5: 355–358PubMedGoogle Scholar
  45. Pizzo PA (1984) Granulocytopenia and cancer therapy. cancer 54: 2649PubMedGoogle Scholar
  46. Platzer E (1990) Human haemotopoetic growth factors. Eur J Haematol 42: 1Google Scholar
  47. Pogothesis CJ, Dexeus FH, Sella A, Amato RJ, Kilbourn RG, Finn L, Gutterman JU (1990) Excalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosyleted recombinant yuman granulocyte macrophage colony-stimulating factor. J Natl Cancer Inst 828: 667Google Scholar
  48. Pont J, Albrecht W (1997) Fertility after chemotherapy for testicular germ cell cancer. Fertil Steril 68: 1–5PubMedGoogle Scholar
  49. Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, Capanna T, Doyle-Lindrud S, Juvidian P, DiPaola RS (2005) A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 62(2): 115–22PubMedGoogle Scholar
  50. Rizzo JD, Lichtin AE, Woolf SH (2002) Use of Epoetin in patients with cancer: evidence-based clinical practice guidelines of American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 1–25Google Scholar
  51. Roberts JT, Fossa SD, Parmar MKB (1991) Results of medical research council phase II study of low dose cisplating and methotrexate in the primary treatment of locally advanced transitional cell carcinoma of the bladder. Br J Urol 68: 162PubMedGoogle Scholar
  52. Rosenow III EC, Meyers JL, Swensen SJ, Pisani RJ (1992) Drug-induced pulmonary disease-an update. Chest 102: 239–250PubMedGoogle Scholar
  53. Sauer H (2000) In: Wilmanns W, Huhn D, Wilms K (Hrsg) Internistische Onkologie. Thieme, Stuttgart New YorkGoogle Scholar
  54. Schaaf D, Schott E (1984) Entsorgung und Vernichtung von Zytostatikaabfällen. Krankenhauspharmazie 5. Jahrgang, Heft 10Google Scholar
  55. Schmoll HJ, Höffken K, Possinger K (1996) Kompendium Internistische Onkologie, Teil 1, 2. Aufl. Springer, Berlin Heidelberg New York TokioGoogle Scholar
  56. Sternberg CN, Yagoda A, Scher HI et al. (1986) Surgical staging and long term survival in patients with advanced transitional cell carcinoma (TCC) of the urothelium treated with M-VAC. Proc ASCO 5: 390Google Scholar
  57. Thurber WA (1989) Offspring of childhood cancer survivors. J Assoc Pediatr Oncol Nurses 6: 17–19PubMedGoogle Scholar
  58. Van Sloten Harwood K, Aisner J (1984) Treatment of chemotherapy extravasation: Current status. Cancer Treat Rep 68: 939Google Scholar
  59. Wander HE, Nagel GA (1985) Mammakarzinome, 3. Aufl. Zuckschwerdt, München Bern WienGoogle Scholar
  60. Wood AJJ (1998) Drug therapy. N Engl J Med 339: 746–754Google Scholar
  61. World Health Organisation (1979) WHO handbook for reporting results of cancer treatment. World Health Organization Offset Publication No. 48, Geneva, Retrieved July y2004Google Scholar

Literatur zu Kap. 10.3

  1. Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, Ecke M, Woltjen HH, Jentsch H, Wieland W, Wander T, Reitz M; German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (DGCIN) (2005) Adjuvant treatment with interleukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92: 843–846PubMedGoogle Scholar
  2. Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA, DeWeese TL (2007) Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy of radiogherapy. Urology 69: 526–531PubMedGoogle Scholar
  3. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23: 4591–4601PubMedGoogle Scholar
  4. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S, Karakiewicz PI (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53: 917–930PubMedGoogle Scholar
  5. Boccardo F, Rubagotti A, Conti G, Battaglia M, Cruciali G, Managanelli A, Ricci S, Lapini A (2007) Prednisone plus gefitinib versus prednisoen plus placebo in the treatment of hormone refractory prostate cancer: a randomized phase-II trial. Oncology 74: 223–228Google Scholar
  6. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L (2005) Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23: 455–460PubMedGoogle Scholar
  7. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21: 679–689PubMedGoogle Scholar
  8. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA (2003) Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 21: 3133–3140PubMedGoogle Scholar
  9. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 25: CD001425Google Scholar
  10. Dalgleish AG, Quatan N, Michael A, Wushishi F, Pandha H (2007) Increased time to progression and sustained PSA velocity responses in a phase II trial in advanced metastatic prostate cancer following treatment with ONY-P1, an allogeneic whole cell vaccine. J Clin Oncol 23(16S): Abs 4726, 2005.Google Scholar
  11. Decobert M, LaRue H, Harel F, Meyer F, Fradet Y, Lacome L (2008) Maintenance bacillus Calmette-Guerin in high-risk nonmuscle invasive baldder cancer: how much is enough? Cancer 113: 710–715PubMedGoogle Scholar
  12. Doehn C, Jocham D (2004) Vaccination immunotherapy-an update. Scand J Surg 93: 163–169PubMedGoogle Scholar
  13. Eaton JD, Perry MJ, Nicolson S, Guckian M, Russel N, Whelan M, Kirby RS (2002) Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 89: 19–26PubMedGoogle Scholar
  14. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investiqators (2007a) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103–2111PubMedGoogle Scholar
  15. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group (2007b) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–134PubMedGoogle Scholar
  16. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271–2281PubMedGoogle Scholar
  17. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J, Doehn C (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell varcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363: 594–599PubMedGoogle Scholar
  18. Joudi FN, Smith BJ, O’Donnell MA; National BCG-Interferon Phase 2 Investigator Group (2006) Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24: 344–348PubMedGoogle Scholar
  19. Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne FM (1992) Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147: 596–600PubMedGoogle Scholar
  20. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163: 1124–1129PubMedGoogle Scholar
  21. Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ (2006) A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 98: 763–769PubMedGoogle Scholar
  22. Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, Rodriguez RH, Gomez JM, Martin MG, Molina JR, Collado AG, Flores N, Isorna S, Pertusa C, Rabadan M, Astobieta A, Camacho JE, Arribas S, Madero R; Club Urologico Espanol de Tratamiento Oncologico (CUETO) (2005) Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 174: 1242–1247PubMedGoogle Scholar
  23. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, trump D; Eastern Cooperative Oncology Group/Intergroup trial (2003) Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21: 1214–1222PubMedGoogle Scholar
  24. Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J, Chakraborty P, Leader D, Whelan M, Pandha H (2005) Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 11: 4469–4478PubMedGoogle Scholar
  25. Motzer RJ, Amato R, Todd M, Hwu WJ, Cohen R, Baselga J, Muss H, Cooper M, Yu R, Ginsberg MS, Needle M (2003) Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21: 99–101PubMedGoogle Scholar
  26. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115–124PubMedGoogle Scholar
  27. Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH (2003) Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 170: S84–S88PubMedGoogle Scholar
  28. Negrier S, Caty A, Lesimple T, Douillard J-Y, Escudier B, Rossi J-F, Viens P, Gomez F (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 18: 4009–4015PubMedGoogle Scholar
  29. Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, Qian J, Steinberg J, Carducci M; Atrasentan Phase 3 Study Group (2008) Phase 3, randomized, controlled trial of attrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113: 2478–2487PubMedGoogle Scholar
  30. O’Donnell MA, Lilli K, Leopold C; National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator Group (2004) Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172: 888–893PubMedGoogle Scholar
  31. Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, Chantada V, Camacho JE, Piñeiro LM, Rodríguez RH, Isorna S, Blas M, Martínez-Piñeiro JA, Madero R; CUETO Group (Club Urológico Español De Tratamiento Oncológico) (2007) A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 52: 1398–1406PubMedGoogle Scholar
  32. Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G, Marubini E (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19: 425–431PubMedGoogle Scholar
  33. Ragde H, Cavanagh WA, Tjoa BA (2004) Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol 172: 2532–2538PubMedGoogle Scholar
  34. Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, Capanna T, Doyle-Lindrud S, Juvidian P, DiPaola RS (2005) A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 62: 115–122PubMedGoogle Scholar
  35. Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, Foon KA, Schwab G, Dutcher J (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22: 3003–3015PubMedGoogle Scholar
  36. Seegenschmidt MH, Müller RP, Höffken K, Junginger T, Sauer H (1999) Dokumentation von Nebenwirkungen in der Onkologie. Dtsch Ärztebl 96: A–489–A495Google Scholar
  37. Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 3:CD003231PubMedGoogle Scholar
  38. Simons JW, Sacks N (2006) Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 24: 419–424PubMedGoogle Scholar
  39. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24: 3089–3094PubMedGoogle Scholar
  40. Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, lacona RB, Kabbinavar FF (2007) A phase-II trial of gefitinib in patients with non-metastatic hormone-refractory cancer. BJU Int 100: 765–769PubMedGoogle Scholar
  41. Swindle PW, Tepes S, Clements J (2004) DC therapy for prostate cancer. Cytotherapy 6: 164–171PubMedGoogle Scholar
  42. Witjes JA, Polou J, Soloway M, Lamm D, Brausi M, Spermon JR, Persad R, Buckley R, Akaza H, Colombel M, Bohle A (2008) Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol Suppl 7: 667–674Google Scholar
  43. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, Isakov L, Flanigan R, Figlin R, Gupta R, Escudier B; C-100-12 RCC Study Group (2008) An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, openlabel, randomised phase III trial. Lancet 372: 145–154PubMedGoogle Scholar
  44. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21: 3127–3132PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2009

Authors and Affiliations

  • Martin Schuler
    • 1
  • Tobias Jäger
    • 2
  • S. Krege
    • 3
  • Herbert Rübben
    • 4
  • Christian Doehn
    • 5
  • Dieter Jocham
    • 6
  1. 1.Klinik für TumorforschungUniversitätsklinikum EssenEssen
  2. 2.Essen
  3. 3.Klinik für UrologieKrankenhaus Maria HilfKrefeld
  4. 4.Klinik u. Poliklinik für UrologieUniversitätsklinikum EssenEssen
  5. 5.Klinik und Poliklinik für UrologieUniversitätsklinikum Schleswig- Holstein (UK S-H)Lübeck
  6. 6.Urologische KlinikUniversitätsklinikum Schleswig-HolsteinLübeck

Personalised recommendations